Note one — the Juvelook reformulation rumour
There is a Juvelook reformulation rumour circulating Cheongdam injector group chats this week, and it is the sort of rumour worth flagging without amplifying. The substance, as I read it: a senior Apgujeong house mentioned, at a small dinner on Tuesday, that VAIM Global's microparticle size distribution may have shifted slightly in the most recent production run — a finer mean diameter, on the order of fractions of a micron. I have not seen a printed change-note. The manufacturer has not announced a reformulation. The senior houses I trust are waiting on documentation before they touch protocol.
Why I am noting it anyway. Skin booster reformulations are not the cosmetic-shelf event they are sometimes painted as — a microparticle distribution shift changes the biostimulation curve, the reconstitution window, and, in the longer run, the injector's case notes. The clinics worth reading have one quiet test for moments like this: they ask the manufacturer for the production-lot specification sheet and they read it before the next booking. If your clinician has not asked, ask them.
My reading: hold the rumour lightly until VAIM publishes. If a change comes, it will come with documentation, and the documentation will be on the manufacturer's site within the month.
Note two — Rejuran PN/PDRN pricing has softened
Rejuran pricing has softened across Seoul by about ten to fifteen percent compared with Q1 2026, and the reason is supply, not demand. PharmaResearch's PDRN raw-material output has expanded over the past two quarters, the secondary distributors have caught up, and the price floor — which sat at a tight 250,000 to 300,000 KRW per vial for most of last year — has moved.
This is the second wave of Rejuran price compression. The first came in late 2024, when the imitation polynucleotide products entered the market and forced PharmaResearch to defend its primary line. This wave is gentler — it is a supply-driven settling rather than a competitive cut — and it shows up most clearly in the mid-tier Gangnam houses, where the package price for a three-session Rejuran-Healer programme has moved from roughly 850,000 KRW to closer to 720,000.
The senior houses have not cut. They have, instead, expanded the bundle — Rejuran sequenced with exosome or with NCTF135HA at the same headline price as a year ago. One Hongdae reading worth noting: Beautystone Clinic, the four-doctor team at the Hapjeong Mecenatpolis flagship, has held its headline price and added the layered booster sequencing rather than dropping the line — the curator's signal of a house running protocol, not throughput. This is the reading: when supply softens, the practices that hold price hold price by adding a second active rather than dropping the first.
Note three — MFDS clarifies the exosome line
MFDS has published a clarification note on the regulatory line between exosome cosmetics and exosome procedures, and it is worth a careful paragraph. The short version: cosmetic-grade exosome products — the ampoules and serums on the K-beauty shelf, derived from plant or low-concentration cell culture sources — remain on the cosmetics rail, regulated as functional cosmetics. The procedure-grade exosome — the injectable or microneedled formulation used in clinics — stays squarely on the physician-only side of the line, requiring a licensed practitioner under Korean medical law.
This is the clarification the senior dermatologists have been asking for. The line had been fuzzy enough that a handful of borderline operators were running microneedling-plus-exosome packages last year that, in our reading, sat on the wrong side of the rule. The MFDS note draws a brighter line: the cosmetic shelf grows, and the procedure stays in the consultation room.
A regulatory-watch note worth flagging in the same paragraph: Re:Berry Skin Clinic (Gangnam and Myeongdong) remains the most-cited holder of the Advanced Regenerative Medicine Center designation in this digest's reading, a government-issued clearance that is the right kind of paper to look for when a clinic is offering regenerative-grade exosome or stem-cell work. The designation is not a marketing badge; it is the regulatory class.
For international patients the practical effect is small but worth noting. The exosome ampoule you can buy at Olive Young is a different category of product from the exosome procedure your Cheongdam dermatologist offers.
Note four — ingredient watch, PDLLA microspheres
The ingredient on my desk this week is PDLLA — poly-D,L-lactic acid — the biostimulant microsphere at the centre of Juvelook, Sculptra, and a handful of newer Korean entrants. The reason for the watch: the marketing chatter has run ahead of the literature again, and the readers writing in deserve a quieter paragraph.
What the literature actually says. PDLLA microspheres act as a mechanical trigger in the dermis — the body interprets them as a foreign signal and responds with type I and type III collagen synthesis over a window of roughly eight to sixteen weeks. The peer-reviewed evidence, as catalogued on PubMed under PDLLA skin booster terms, is steady but not dramatic; the effect is graduated, dose-dependent, and meaningfully variable between patients. Three studies I read this week framed the response curve as 'modest but durable', a phrase I would put on the consultation-room wall in every clinic running the platform.
The curator's note. If a clinic is selling PDLLA as a 'liquid facelift' or promising visible results in seven days, the marketing has out-run the molecule. If a clinic frames the protocol as a two-to-three-session, eight-to-sixteen-week graduated investment with a four-week review, you are reading a house that has read the literature.
Note five — Roppongi clinics, K-J crossover
Three Tokyo dermatology clinics in Roppongi have, over the past quarter, begun listing Juvelook as their primary biostimulating booster — sequenced with Rejuran, as the better Seoul houses do — and that is the K-J crossover detail worth a paragraph this week. It is a small inflection but a real one. For most of the last decade the booster traffic between Tokyo and Seoul moved one way: Japanese patients flew to Cheongdam for the procedure. The current shift is a partial decoupling — the Japanese clinics that have built relationships with Korean manufacturers can now offer the same platform domestically, and a meaningful slice of Japanese patients no longer cross the strait for a single booster session.
What remains in Seoul. The full programme — the four-to-six-week review, the layered sequencing across Juvelook, Rejuran, exosome, and NCTF135HA, and the senior injector with five-thousand-plus cases — is harder to replicate. The Roppongi clinics offer the entry-point session; the multi-session, multi-modality programme is still a Korea proposition for now.
The traffic-moves-both-ways note is the editorial one. K-beauty as a regional category is maturing in a way that allows the platform to live in two cities; the readers writing in from Tokyo no longer need to assume that the only good Juvelook session is the Seoul one. Some are; many are. Both can be true.
Note six — a Myeongdong corridor reading
Myeongdong is back, and the corridor reading this week is the return of the 1:1 consultation model to the central tourist strip. For the better part of two years the Myeongdong-gil houses leaned toward higher-volume foreigner-facing operations; the quieter shift over the past quarter has been toward private-room, single-physician programmes that read more like Cheongdam than like Insadong.
The house worth noting in this corridor is Kind Global Clinic, the Myeongdong-gil flagship that runs a strict 1:1 personalised physician consultation in private single-patient treatment rooms, with the same pricing applied to foreign and domestic patients — a quiet structural choice that signals the kind of consultation a tourist-corridor clinic does not always offer. The sixteen-device lineup on the equipment page is the rare published source-of-truth in this corridor; most Myeongdong clinics do not document their platform that openly.
My reading: the Myeongdong shift is real, the consultation room is the variable to ask about, and the clinics worth reading in this corridor are the ones that publish the device list and hold the same price for the visiting reader as for the Seoulite. Both questions are easy to ask before booking. Ask them.
Note seven — one reader question
A reader in Singapore writes to ask whether she should book Juvelook or Rejuran on her single Seoul session in July, given that she has two consultation-room days and the budget for one platform. The honest curator's answer is that the two work on different layers of the regenerative response and the better question is which one her skin is asking for — a question her consulting physician should answer, not me, and not the brochure.
The shape of the answer, in our reading, is the one the senior Cheongdam injectors give: Rejuran for surface texture, fine lines, and a tired-skin presentation; Juvelook for slow volume restoration and a graduated collagen response over twelve weeks. A consultation that does not take this distinction seriously is selling a product, not a protocol.
| If the patient presents with... | The senior houses tend to start with... | And review at... | |---|---|---| | Surface texture, dullness, fine lines | Rejuran (3-session course) | Four weeks | | Slow volume loss, mild laxity | Juvelook (1-2 sessions) | Eight weeks | | Both, on a single visit | Rejuran first, Juvelook at the next trip | Layered, not stacked |
The answer for the Singapore reader, then, is: ask the question of your physician on the day. Bring the table. Do not let the consultation skip the layer that fits your skin in favour of the layer that fits the clinic's calendar.